Miyata Yasuyoshi, Ohba Kojiro, Kanda Shigeru, Nomata Koichiro, Eguchi Jiro, Hayashi Tomayoshi, Kanetake Hiroshi
Department of Urology, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Virchows Arch. 2006 Jun;448(6):822-9. doi: 10.1007/s00428-006-0198-1. Epub 2006 Apr 12.
The prostaglandin E2 receptor, EP4 receptor (EP4R), plays an important role in the development of transitional cell carcinoma of the upper urinary tract (TCC-UUT). However, the clinical significance of other EP receptors (EP1R-3R) is not clear. Furthermore, the pathological function of EP receptors in such patients is not understood. In the present study, we examined the expression of EP1R-3R in 101 TCC-UUT tissues by immunohistochemistry. Furthermore, we defined the relationship between cyclooxygenase (COX)-2 and EP receptor expression, proliferation index (PI), microvessel density (MVD), and expression of metalloproteinase-2 (MMP-2), urokinase-type plasminogen activator (uPA), and exon v6 containing CD44 isoform (CD44 v6) by multivariate analysis. The expression of EP1R, EP2R, and EP3R was positive in 20 (19.8%), 26 (25.7%), and 14 (13.9%) tumor samples, respectively. Expression of these receptors was not associated with pathological findings or survival. COX-2 and EP4R were independently associated with MVD and MMP-2, and uPA or PI and MMP-2, respectively. Other EP receptors were not influenced by any factors. Our results suggest that EP1R-3R play a minimal role in cancer progression in patients with TCC-UUT. On the other hand, EP4R regulates tumor progression via cancer cell proliferation and MMP-2, distinct from COX-2.
前列腺素E2受体,即EP4受体(EP4R),在上尿路移行细胞癌(TCC - UUT)的发生发展中起重要作用。然而,其他EP受体(EP1R - 3R)的临床意义尚不清楚。此外,此类患者中EP受体的病理功能也尚不明确。在本研究中,我们通过免疫组织化学检测了101例TCC - UUT组织中EP1R - 3R的表达。此外,我们通过多变量分析确定了环氧合酶(COX)-2与EP受体表达、增殖指数(PI)、微血管密度(MVD)以及金属蛋白酶-2(MMP - 2)、尿激酶型纤溶酶原激活剂(uPA)和含CD44异构体v6(CD44 v6)的外显子v6表达之间的关系。EP1R、EP2R和EP3R在肿瘤样本中的阳性表达率分别为20例(19.8%)、26例(25.7%)和14例(13.9%)。这些受体的表达与病理结果或生存率无关。COX - 2和EP4R分别独立地与MVD和MMP - 2以及uPA或PI和MMP - 2相关。其他EP受体不受任何因素影响。我们的结果表明,EP1R - 3R在TCC - UUT患者的癌症进展中作用极小。另一方面,EP4R通过癌细胞增殖和MMP - 2调节肿瘤进展,这与COX - 2不同。